DHCR7 gene targeting inhibitor and application thereof in preparation of drugs for treating acute myelogenous leukemia

By designing RNA interference inhibitors targeting the DHCR7 gene, the problem of drug resistance in AML cells has been solved, achieving inhibition of AML cell proliferation and induction of apoptosis, providing new treatment and diagnostic methods.

CN120983461APending Publication Date: 2025-11-21THE 1ST AFFILIATED HOSPITAL OF SHIHEZI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511175913.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-21
Publication Date
2025-11-21

AI Technical Summary

Technical Problem

In the existing technology, drug resistance in acute myeloid leukemia (AML) cells is closely related to lipid metabolism reprogramming. The role of the DHCR7 gene in AML has not been fully studied, and there is a lack of effective targeted therapies.

Method used

We will design RNA interference substances (such as shRNA) targeting the DHCR7 gene as targeted inhibitors to suppress the expression of the DHCR7 gene, thereby inhibiting AML cell proliferation and inducing apoptosis, and develop corresponding drug formulations and diagnostic kits.

Benefits of technology

It significantly inhibits AML cell proliferation and induces apoptosis, providing a new drug target and auxiliary diagnostic method for AML treatment. By targeting and inhibiting DHCR7 gene expression, it improves patient prognosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120983461A_ABST
    Figure CN120983461A_ABST
Patent Text Reader

Abstract

The invention discloses a target inhibitor of a DHCR7 gene and application of the target inhibitor in preparation of a medicine for treating acute myelogenous leukemia, and relates to the technical field of biological medicines, and the target inhibitor is an RNA interfering substance capable of inhibiting the DHCR7 gene; the RNA interfering substance is a first shRNA (short hairpin ribonucleic acid) or a second shRNA; the first shRNA and the second shRNA are both targeted to a DHCR7 gene; the first shRNA comprises a double-stranded region formed by a sequence as shown in SEQ ID NO.7 or a complementary sequence of the sequence as shown in SEQ ID NO.7; the second shRNA comprises a double-stranded region formed by a sequence shown in SEQ ID NO.10 or a complementary sequence of the sequence shown in SEQ ID NO.10. Expression of endogenous DHCR7 is inhibited through the designed RNA interfering substance, so that proliferation of AML cells is remarkably inhibited, apoptosis of the AML cells is induced, a new theoretical basis and a new drug target are provided for treatment of the AML, and meanwhile, a new method is provided for auxiliary diagnosis of the AML.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to a targeted inhibitor of the DHCR7 gene and its application in the preparation of drugs for the treatment of acute myeloid leukemia. Background Technology

[0002] Acute myeloid leukemia (AML) is the most aggressive hematologic malignancy in adults, characterized by rapid disease progression, high relapse rates, and poor overall prognosis. Currently, chemotherapy-based induction and consolidation therapy is the standard treatment for AML. However, treatment resistance poses a major clinical challenge. Studies have shown that this resistance is closely related to the significant lipid metabolic reprogramming prevalent in AML cells. This reprogramming is mainly manifested as aberrant activation of the de novo fatty acid synthesis pathway, enhanced exogenous lipid uptake, and increased lipid droplet biogeneration and storage. This adaptive metabolic alteration continuously provides the necessary energy (ATP) and precursors for membrane phospholipid biosynthesis for the rapid proliferation of leukemia cells, while simultaneously conferring an intrinsic survival advantage and chemotherapy resistance.

[0003] With the development and application of genetic engineering technology, targeted therapy strategies against tumor-specific expressed genes have become an important direction in cancer treatment research. The core of such strategies is to specifically block the transcription or translation of the target gene by introducing nucleic acid molecules (such as DNA or RNA) complementary to the target gene's mRNA, thereby inhibiting its abnormal expression and achieving tumor treatment. Therefore, identifying key genes that are specifically highly expressed in acute myeloid leukemia cells and drive malignant progression, and elucidating their molecular mechanisms, is crucial for developing effective treatments.

[0004] DHCR7 (7-dehydrocholesterol reductase), the rate-limiting enzyme in cholesterol biosynthesis, is highly expressed in various tumors. It catalyzes the conversion of 7-dehydrocholesterol into cholesterol, providing a crucial material basis for the synthesis of membrane structures required for rapid tumor cell division and directly promoting their malignant proliferation. However, current research on the mechanism of action of DHCR7 in the development and progression of acute myeloid leukemia (AML) is insufficient, and its application value in AML gene therapy has not been reported. Therefore, developing therapeutic drugs targeting DHCR7 is a critical issue that urgently needs to be addressed. Summary of the Invention

[0005] Based on the technical problems existing in the background art, the present invention proposes a targeted inhibitor of the DHCR7 gene and its application in the preparation of drugs for the treatment of acute myeloid leukemia. By inhibiting the expression of the DHCR7 gene, the proliferation of AML cells can be effectively inhibited and apoptosis can be induced.

[0006] This invention proposes the application of a DHCR7 gene targeting inhibitor in the preparation of a drug for treating acute myeloid leukemia. The targeting inhibitor is an RNA interference substance that can inhibit the DHCR7 gene.

[0007] Preferably, the RNA interference substance comprises a first shRNA or a second shRNA; and both the first shRNA and the second shRNA target the DHCR7 gene.

[0008] Preferably, the first shRNA contains a double-stranded region formed by the sequence shown in SEQ ID NO.7 or its complementary sequence; the second shRNA contains a double-stranded region formed by the sequence shown in SEQ ID NO.10 or its complementary sequence.

[0009] Preferably, the dosage form of the drug is any pharmacologically acceptable dosage form.

[0010] Preferably, the dosage of the drug is any pharmacologically acceptable dosage.

[0011] The present invention proposes a kit for the detection of acute myeloid leukemia, wherein the kit uses the DHCR7 gene or its expression product as the detection target and contains primer pairs capable of specifically amplifying the target region of the DHCR7 gene; The upstream primer sequence is shown in SEQ ID NO.1; The downstream primer sequence is shown in SEQ ID NO.2.

[0012] Beneficial technical effects of the present invention: This invention significantly inhibits AML cell proliferation and induces apoptosis by suppressing endogenous DHCR7 expression through a designed RNA interference substance, providing a new theoretical basis and drug target for AML treatment, and also offering a new method for the auxiliary diagnosis of AML. Attached Figure Description

[0013] Figure 1 This invention presents the expression, prognostic significance, and prediction model of DHCR7 in AML; where A is the DHCR7 pan-cancer expression profile analysis (SangerBox), B is the association between DHCR7 expression level and survival prognosis of AML patients (Kaplan-Meier Plotter), and C is the DHCR7 nomogram prediction model for survival prognosis of AML patients (constructed based on the TCGA-LAML dataset). Figure 2This invention presents the expression difference of DHCR7 in peripheral blood mononuclear cells (PBMCs) from normal individuals and AML patient samples; wherein, A represents the protein expression level of DHCR7 in normal individuals and AML patients detected by Western blot, B is a statistical graph of quantitative analysis by Western blot, and C represents the mRNA expression level of DHCR7 in normal individuals and AML patients detected by real-time quantitative PCR. Figure 3 The expression difference of DHCR7 in normal human PBMC and AML cell lines proposed in this invention; wherein, A is the protein expression level of DHCR7 in normal human and AML cell lines detected by Western blot, B is the corresponding quantitative statistical analysis graph of protein expression, and C is the mRNA expression level of DHCR7 in normal human and AML cell lines detected by real-time fluorescence quantitative PCR. Figure 4 The effect of the DHCR7 inhibitor proposed in this invention on AML cell growth; Figure 5 Flow cytometry plot of the DHCR7 inhibitor proposed in this invention on apoptosis in AML cells; Figure 6 The effect of the DHCR7 inhibitor proposed in this invention on the expression of apoptosis-related proteins in AML cells; Figure 7 The effect of the DHCR7 inhibitor proposed in this invention on AML cell proliferation; Figure 8 The effect of the DHCR7 inhibitor proposed in this invention on M2 polarization of macrophages. Detailed Implementation

[0014] The present invention will be further explained below with reference to specific embodiments. Example 1

[0015] The following methods were used to explore DHCR7 as a biomarker for poor prognosis in AML: The pan-cancer expression profile of DHCR7 was analyzed using the SangerBox online tool. The results showed that DHCR7 expression was significantly upregulated in various tumor tissues, including AML. Figure 1 Part A of the study). Based on this finding, we evaluated the impact of DHCR7 expression level on the prognosis of AML patients using the KM survival curve online tool, and found that patients with high DHCR7 expression had a significantly shorter overall survival than patients with low expression (Part A of the study). Figure 1 Part B of the dataset). To further quantify the prognostic value of DHCR7, we constructed a DHCR7 prognostic nomogram model based on the TCGA-LAML dataset. Figure 1 Part C).

[0016] The test results are as follows Figure 1 As shown, DHCR7 is highly expressed in a variety of cancers (especially AML), and in AML patients, high DHCR7 expression is an independent predictor of poor prognosis. Example 2

[0017] Furthermore, based on the conclusions of Example 1, the design of the DHCR7 gene inhibitor and the preparation of the interference vector are carried out using the following specific methods: First, an interference sequence for the DHCR7 gene was designed. Then, two target gene sequences specifically inhibiting DHCR7 gene expression were designed, targeting the human DHCR7 gene, as follows: The first target gene sequence is: 5'-CGTGATTGACTTCTTCTGGAA-3' (SEQ ID No. 3).

[0018] The second target gene sequence is: 5'-ACTTCAAGCTGTTCTTCAATG-3' (SEQ ID No. 4).

[0019] The two target gene sequences were compared and analyzed by inputting them into NCBI's nucleotide blast homology analysis tool. The results showed that the two target gene sequences did not have high homology with other human mRNA genes and could be used as specific sequences for specific interference with the DHCR7 gene.

[0020] Based on the above sequence targeting and inhibiting DHCR7 gene expression, an inhibitor shRNA for targeting and inhibiting DHCR7 gene expression was further designed and synthesized. The inhibitor corresponding to the first target gene sequence is denoted as shDHCR7#1. This inhibitor includes a sense strand and an antisense strand, and the specific sequences are as follows: Sense strand: 5'-GATCGCGTGATTGACTTCTTCTGGAACTCGAGTTCCAGAAGAAGTCAATCACGTTTTTT-3' (SEQ ID No. 5).

[0021] Antisense strand: 5'AATTAAAAAACGTGATTGACTTCTTCTGGAACTCGAGTTCCAGAAGAAGTCAATCACG-3' (SEQ ID No. 6).

[0022] The transcription product sequence of shDHCR7#1 is: 5'-CGTGATTGACTTCTTCTGGAACTCGAGTTCCAGAAGAAGTCAATCACGTT-3' (SEQ ID No. 7).

[0023] The inhibitor corresponding to the second target gene sequence is denoted as shDHCR7#2. This inhibitor includes both sense and antisense strands, and the specific sequences are as follows: Chain of Justice: 5'-GATCGACTTCAAGCTGTTCTTCAATGCTCGAGCATTGAAGAACAGCTTGAAGTTTTTTT-3' (SEQ ID No. 8).

[0024] Antisense strand: 5'-AATTAAAAAAACTTCAAGCTGTCTTCAATGCTCGAGCATTGAAGAACAGCTTGAAGT-3' (SEQ ID No. 9).

[0025] The transcript sequence of shDHCR7#2 is: 5'-ACTTCAAGCTGTTCTTCAATGCTCGAGCATTGAAGAACAGCTTGAAGTT-3' (SEQ ID No. 10).

[0026] Plasmids were designed and synthesized based on the sequence information of shDHCR7#1 and shDHCR7#2, respectively, to serve as DHCR7 gene inhibitors. The negative control shNC sequence was a random sequence. When AML cells reached 50% confluence, plasmids carrying a U6 promoter-driven shRNA expression cassette, GFP fluorescent label, and PURO resistance gene were transfected into the cells to achieve specific silencing of the DHCR7 gene. The necessary plasmids and Opti-MEM were prepared for transfection. TM Lipofectamine 3000 (Life Technologies) transfection reagent. Tube A: Dissolve 1 μg of plasmid DNA in 50 μl of Opti-MEM per well. TM After standing for 5 minutes, tube B: dissolve 2 μl of Lipofectamine 3000 in 50 μl of Opti-MEM in one well. TM Add all the liquid from tube A to tube B, mix gently, and let stand at room temperature for 10-15 minutes (to form a DNA-liposome complex). Remove the culture medium from the cells to be transfected and use Opti-MEM. TMWash cells once, and add 400 μl of fresh serum-free medium to each well. Add approximately 100 μl of the mixture evenly to each well and gently shake to mix. The final volume per well is 500 μl (mixture + medium). Incubate at 37°C for 4-6 hours, then replace with serum-containing complete medium and continue culturing. After 48 hours, select cells using medium containing the antibiotic puromycin at a concentration of 10 μg / mL. Cell lines capable of stably silencing the DHCR7 gene were obtained approximately one week later. In subsequent experiments, cells were divided into three groups: shNC group, shDHCR7#1 group, and shDHCR7#2 group. Example 3

[0027] The expression of the DHCR7 gene mRNA in normal human PBMCs, AML patient samples, and AML cell lines was detected by real-time quantitative PCR. The specific method is as follows: (1) Peripheral blood mononuclear cells (PBMCs) were isolated using the Ficoll method. 7 ml of human lymphocyte separation medium was added to a 15 ml centrifuge tube. Sterile PBS buffer was added to the EDTA-anticoagulated peripheral blood at a 1:1 volume ratio and gently mixed. The mixture was then transferred to a centrifuge tube containing the human lymphocyte separation medium. The tube was centrifuged at 500 g for 30 minutes. A Pasteur pipette was inserted parallel to the white membrane layer and slowly aspirated, transferring the white membrane layer to a new centrifuge tube. Three volumes of pre-chilled PBS were added and gently mixed. The tube was centrifuged at 500 g for 10 minutes. The supernatant was discarded, and 1 ml of PBS was added to resuspend the precipitate. The precipitate was transferred to a 1.5 ml centrifuge tube. If red blood cell precipitate was present, red blood cell lysis buffer was added and the tube was lysed on ice for 20 minutes. The tube was then centrifuged at 1200 g for 3 minutes to obtain human peripheral blood PBMCs.

[0028] (2) Total RNA extraction from cells using the Trizol method: Wash the collected cells with cold PBS, add 1 ml of Trizol reagent and pipette several times. Under a microscope, observe that the cells are in the form of oil droplets (fully lysed). Then transfer them to a 1.5 ml EP tube and let them stand for 5 minutes to allow them to fully lyse. Add 200 μl of chloroform to the sample and shake vigorously manually. Let it stand at room temperature for 3 minutes. Centrifuge at 12000 g for 15 minutes at 4°C. Take the upper aqueous phase and transfer it to a new EP tube. Add 500 μl of isopropanol, mix by inverting, and let it stand at room temperature for 10 minutes. Centrifuge at 12000 g for 15 minutes at 4°C and discard the supernatant. Add 1 ml of pre-cooled 75% ethanol. Centrifuge at 7500 g for 5 minutes at 4°C. Dry for 15 minutes and add 20-50 μl of DEPC water before detecting the RNA concentration.

[0029] (3) RNA was reverse transcribed into cDNA, then amplified, and the CT value was measured. GAPDH was used as an internal reference, and the relative expression level of DHCR7 was expressed as 2-ΔΔCt.

[0030] The test results are as follows Figure 2 Part C and Figure 3In Part C, real-time quantitative PCR analysis showed that the expression level of DHCR7 gene mRNA in AML patients and their cell lines was significantly higher than that in normal human peripheral blood PBMCs (*P<0.05). Data are expressed as mean ± standard deviation (n=3).

[0031] Based on the high expression of DHCR7 in AML patients and cell lines, we have developed a real-time quantitative PCR diagnostic kit (specific primers: upstream primer 5'-GCTGCAAAATCGCAACCCAA-3' (SEQ ID NO.1); downstream primer 5'-GCTCGCCAGTGAAAACCAGT-3' (SEQ ID NO.2)), which can be used to detect the amplification and expression of DHCR7 in clinical samples, providing supporting evidence for the clinical diagnosis of AML. Example 4

[0032] The expression level of DHCR7 protein in peripheral blood PBMCs from healthy individuals, AML patient samples, and AML cell lines was detected by Western blot. The specific methods are as follows: PBMC cells were collected, RIPA protein lysis buffer was added, and the mixture was shaken and incubated on ice for 30 min. The cells were then centrifuged at 12000g for 30 min at 4°C. The supernatant was collected, and 20 μL of the supernatant was used to determine the protein concentration using the BCA method. The remaining supernatant was mixed with 5x loading buffer (1:4) and boiled for 5 min to denature the protein. The denatured protein was separated by gel electrophoresis with 4-20% SDS-polyacrylamide. The protein was transferred to a PVDF membrane and blocked with 5% skim milk for 1 h. The membrane was then specifically bound to antibodies against DHCR7 and GAPDH (purchased from Invitrogen, #PA5-48204, #PA1-987), and incubated overnight at 4°C. The membrane was washed with TBST for 10 min three times, and the corresponding secondary antibody was added. The membrane was then incubated on a shaker at room temperature for 1 h. ECL luminescence was performed, and the cells were photographed and quantitatively analyzed using ImageJ software.

[0033] The test results are as follows Figure 2 Part A and Figure 3 In Part B, compared with normal human peripheral blood mononuclear cells (PBMCs), the expression level of DHCR7 protein was significantly increased in AML patients and their cell lines (*P<0.05). Data are expressed as mean ± standard deviation (n=3). Example 5

[0034] The growth capacity of AML cells in the control group (shNC group) and the inhibitor groups (shDHCR7#1 group and shDHCR7#2 group) was measured respectively.

[0035] Cell growth capacity was assessed using the CCK8 assay: Untreated AML cells and DHCR7 inhibitor-treated AML cells were seeded at a density of 3000 cells per well in 96-well plates (each well containing 100 μL of culture medium), and the absorbance (OD value) at 450 nm was measured daily for 5 consecutive days.

[0036] The test results are as follows Figure 4 As shown in the figure, the cell proliferation assay results indicated that the cell proliferation capacity of the DHCR7 inhibitor treatment group was significantly reduced compared with the control group. This result suggests that the application of DHCR7 inhibitors can significantly inhibit the growth capacity of AML cells. Example 6

[0037] Apoptosis in AML cells was detected by flow cytometry using Annexin V-APC / PI double staining. The experimental groups were divided into a control group and an inhibitor treatment group. The specific methods are as follows: Collect cells and gently resuspend them in PBS. Take 1×10⁵ cells and add 100 μL of 1xAnnexin V binding buffer to resuspend the cells. Add 5 μL of Annexin V-APC and 5 μL of PI and mix gently. Incubate at room temperature in the dark for 15 minutes. After incubation, add 400 μL of 1xAnnexin V binding buffer to resuspend the cells and immediately perform analysis.

[0038] The test results are as follows Figure 5 As shown, after the application of DHCR7 gene inhibitors, the apoptosis rate in the inhibitor group was significantly increased compared with the control group; suggesting that the application of DHCR7 gene inhibitors can significantly induce apoptosis. Example 7

[0039] The effect of the DHCR7 inhibitor group on apoptosis proteins in AML cells was detected by Western blot assay, as follows: Cells were collected, RIPA protein lysis buffer was added, and the mixture was vortexed and incubated on ice for 30 min. The mixture was then centrifuged at 12000g for 30 min at 4°C. The supernatant was collected, and 20 μL of the supernatant was used to determine the protein concentration using the BCA method. The remaining supernatant was mixed with 5x loading buffer (1:4) and boiled for 5 min to denature the protein. The denatured protein was separated by gel electrophoresis with 4-20% SDS-polyacrylamide at 150V for 60 min. The membrane was then transferred at 300mA for 90 min. The membrane was blocked with 5% skim milk for 1 h. The membrane was then coated with Cleaved caspase 3 and caspase 4, respectively. 3. The antibodies specifically bind to the four proteins DHCR7 and β-actin (purchased from Proteintech, #19677-1-AP, #25128-1-AP, #66009-1-lg; purchased from Invitrogen, #PA5-48204). After complete binding, incubate overnight at 4°C; wash with TBST for 10 min, 3 times, add the corresponding secondary antibody, and incubate on a shaker at room temperature for 1 h; perform ECL luminescence, photograph, and quantitative analysis using ImageJ software.

[0040] The test results are as follows Figure 6 As shown, the expression level of Cleaved caspase 3, a key apoptosis protein, in AML cells treated with the DHCR7 inhibitor was significantly higher than that in the control group, suggesting that the inhibitor can induce apoptosis in AML cells. Example 8

[0041] The proliferative activity of the DHCR7 inhibitor group against AML cells was detected by immunofluorescence EdU assay, as follows: Cells were collected and incubated with EdU working solution for 2.5 hours; fixed with paraformaldehyde for 15 minutes and then incubated with immunofluorescence permeation solution for 15 minutes; Click reactant was added and incubated in the dark for 30 minutes; then Hoechst 33342 was added and incubated for 10 minutes; followed by fluorescence detection.

[0042] The test results are as follows Figure 7 As shown, AML cells treated with the DHCR7 inhibitor showed significantly reduced cell viability compared to the control group, suggesting that the inhibitor can suppress AML cell proliferation. Example 9

[0043] Flow cytometry was used to detect the effect of DHCR7 inhibitors on the polarization of M2 macrophages. Macrophages can be divided into pro-inflammatory M1 type and pro-cancer M2 type. In the tumor microenvironment, M2 macrophages play a pro-cancer role. To study its regulation, we treated the human monocyte cell line THP-1 with DHCR7 inhibitors and induced it to differentiate and polarize into macrophages in vitro. The experimental groups were divided into a control group and an inhibitor-treated group. The specific methods are as follows: Collect human THP-1 cells and gently resuspend them in PBS. Take 1 x 10⁵ cells and add 100 μL of PBS buffer to resuspend the cells. Add 5 μL of Brilliant Violet 421-labeled anti-human CD206 antibody and 5 μL of PE-labeled anti-human CD163 antibody, mix gently, and incubate at room temperature in the dark for 15 minutes. After incubation, add 400 μL of PBS buffer to resuspend the cells and immediately perform analysis.

[0044] The test results are as follows Figure 8 As shown, after applying the DHCR7 gene inhibitor, the proportion of M2 macrophages in the inhibitor group was significantly reduced compared with the control group, indicating that the inhibitor can effectively inhibit the polarization of M2 macrophages.

[0045] Although embodiments of this application have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and spirit of this application. The scope of this application is defined by the appended claims and their equivalents, all of which should be included within the protection scope of this application.

Claims

1. The application of a DHCR7 gene-targeting inhibitor in the preparation of a drug for treating acute myeloid leukemia, characterized in that, The targeted inhibitor is an RNA interference substance that can inhibit the DHCR7 gene.

2. The application of the DHCR7 gene targeting inhibitor according to claim 1 in the preparation of a drug for treating acute myeloid leukemia, characterized in that, The RNA interference substance is a first shRNA or a second shRNA; and both the first shRNA and the second shRNA target the DHCR7 gene. The first shRNA contains a double-stranded region formed by the sequence shown in SEQ ID NO.7 or its complementary sequence; The second shRNA contains a double-stranded region formed by the sequence shown in SEQ ID NO.10 or its complementary sequence.

3. The application of the DHCR7 gene targeting inhibitor according to claim 1 in the preparation of a drug for treating acute myeloid leukemia, characterized in that, The dosage form of the drug is any pharmacologically acceptable dosage form.

4. The use of the DHCR7 gene targeting inhibitor according to claim 1 in the preparation of a drug for treating acute myeloid leukemia, characterized in that, The dosage of the drug is any pharmacologically acceptable dosage.

5. A reagent kit for detecting acute myeloid leukemia, characterized in that, The kit uses the DHCR7 gene or its expression product as the detection target and contains primer pairs that can specifically amplify the target region of the DHCR7 gene. The upstream primer sequence is shown in SEQ ID NO.1; The downstream primer sequence is shown in SEQ ID NO.2.